ArticleFrontiers in pharmacology2025
Ondansetron: a potential intervention for improving clinical outcomes in stroke patients.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Stroke is a major global public - health problem. It is a cerebrovascular disease with sudden onset, high prevalence, and high rates of death and disability. Ondansetron (a 5 - HT3 receptor antagonist) an antiemetic, has recently been indicated in studies to have the ability to influence neurotransmitter imbalance, towardly have more effective against vomiting in stroke patients. However, its impact on stroke patients' clinical outcomes remains unclear. This study uses real - world data to evaluate ondansetron's effect on stroke patients' clinical outcomes. Findings could lead to new treatments and better outcomes. Methods: This study was a retrospective cohort analysis involving adult patients who experienced a stroke, categorized into two groups: the ondansetron group and the non-ondansetron group. To ensure the baseline characteristics were balanced, propensity score matching (PSM) was utilized. The mortality rate was assessed using multivariable Cox regression models along with Kaplan-Meier survival curves. Additionally, subgroup analyses were performed to examine the consistency of the findings. Results: A total of 5,297 stroke patients were included in this study, among which 3,926 stroke patients received ondansetron treatment on the first day of admission to the intensive care unit (ICU), and 1,371 did not receive this drug treatment. After PSM, 2,628 patients were paired. The analysis results showed that the use of ondansetron on the first day of admission to the ICU significantly reduced the 30-day mortality rate (hazard ratio [HR] 0.73, 95% confidence interval [CI]: 0.59-0.92, P < 0.05). Meanwhile, the 60-day mortality rate also decreased significantly (HR 0.73, 95% CI: 0.60-0.90, P < 0.05). Conclusion: Treatment using ondansetron is linked to an enhancement in the overall prognosis for stroke patients. Those who are administered ondansetron on the initial day of their ICU admission experience a notably lower mortality rate. The results of this research provide a compelling and valuable addition to the conventional stroke treatment protocol, holding considerable clinical importance and scientific research relevance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.